Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VIVS VivoSim Labs Inc.
- Stocks
- Healthcare
- NASDAQ: VIVS
Price (delayed)
$1.82
Market cap
$4.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.7
Enterprise value
-$5.65M
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are
Highlights
The equity has soared by 191% year-on-year
VIVS's quick ratio has soared by 102% YoY
VIVS's gross margin is down by 3.5% YoY
Key stats
What are the main financial stats of VIVS
Market
Valuations
Earnings
Shares outstanding
2.6M
Market cap
$4.73M
Enterprise value
-$5.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.25
Price to sales (P/S)
18.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-39.26
Revenue
$144,000
Gross profit
$139,000
Operating income
-$12.62M
Net income
-$2.49M
EBIT
-$2.48M
EBITDA
-$1.78M
Free cash flow
-$474,000
Per share
Balance sheet
Liquidity
EPS
-$1.7
EPS diluted
-$1.7
Free cash flow per share
-$0.32
Book value per share
$7.21
Revenue per share
$0.1
TBVPS
$10.01
Total assets
$14.65M
Total liabilities
$4.16M
Debt
$1.07M
Equity
$10.49M
Working capital
$8.39M
Debt to equity
0.1
Current ratio
3.25
Quick ratio
3.34
Net debt/EBITDA
5.84
Margins
Efficiency
Dividend
EBITDA margin
-1,234.7%
Gross margin
96.5%
Net margin
-1,727.8%
Operating margin
-8,761.1%
Return on assets
-28.7%
Return on equity
-46.9%
Return on invested capital
-154.2%
Return on capital employed
-22.7%
Return on sales
-1,719.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VIVS stock price
How has the VivoSim Labs stock price performed over time
Intraday
-1.09%
1 week
4%
1 month
-4.21%
1 year
-84.2%
YTD
-67.03%
QTD
-18.75%
Financial performance
How have VivoSim Labs's revenue and profit performed over time
Revenue
$144,000
Gross profit
$139,000
Operating income
-$12.62M
Net income
-$2.49M
Gross margin
96.5%
Net margin
-1,727.8%
VIVS's net margin has surged by 87% year-on-year and by 83% since the previous quarter
The net income has surged by 83% year-on-year and by 80% since the previous quarter
The operating margin is up by 37% year-on-year and by 15% since the previous quarter
The revenue has grown by 32% YoY and by 18% from the previous quarter
Price vs fundamentals
How does VIVS's price correlate with its fundamentals
Growth
What is VivoSim Labs's growth rate over time
Valuation
What is VivoSim Labs stock price valuation
P/E
N/A
P/B
0.25
P/S
18.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-39.26
The EPS has soared by 91% year-on-year and by 83% since the previous quarter
The equity has soared by 191% year-on-year
The stock's price to book (P/B) is 96% less than its last 4 quarters average of 5.9 and 90% less than its 5-year quarterly average of 2.5
The P/S is 78% below the last 4 quarters average of 83.2
The revenue has grown by 32% YoY and by 18% from the previous quarter
Efficiency
How efficient is VivoSim Labs business performance
The ROS has soared by 87% year-on-year and by 83% since the previous quarter
The ROE has soared by 86% from the previous quarter and by 76% YoY
VIVS's return on assets has surged by 85% since the previous quarter and by 80% year-on-year
VIVS's return on invested capital has surged by 73% since the previous quarter and by 65% year-on-year
Dividends
What is VIVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VIVS.
Financial health
How did VivoSim Labs financials performed over time
The total assets has surged by 131% year-on-year
VIVS's quick ratio has soared by 102% YoY
VIVS's debt is 90% smaller than its equity
The equity has soared by 191% year-on-year
The debt to equity has plunged by 97% from the previous quarter and by 74% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.